Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been assigned an average recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $86.80.

A number of analysts have weighed in on the stock. JMP Securities decreased their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $41.14 on Friday. Structure Therapeutics has a 52 week low of $26.61 and a 52 week high of $74.21. The stock has a market capitalization of $2.35 billion, a P/E ratio of -54.85 and a beta of -3.53. The stock has a fifty day moving average of $39.57 and a 200-day moving average of $39.76.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. On average, research analysts forecast that Structure Therapeutics will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sandia Investment Management LP bought a new position in Structure Therapeutics in the 2nd quarter worth about $39,000. Assetmark Inc. increased its position in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the last quarter. Quarry LP purchased a new stake in Structure Therapeutics in the second quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG purchased a new position in Structure Therapeutics in the 3rd quarter worth approximately $206,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.